Welcome to our dedicated page for Vystar news (Ticker: VYST), a resource for investors and traders seeking the latest updates and insights on Vystar stock.
Vystar Corporation reports news about its diversified innovation businesses, including RxAir UV-C air purification products, Vytex Natural Rubber Latex, Fluid Energy Solutions and GoPaid collectibles monetization. Company updates commonly address eco-friendly product development, air purification certifications and applications, collectible-tokenization initiatives, and technology uses in water filtration, flow metering and air processing.
Vystar news also includes public-company subjects such as capital-structure disclosure, shareholder voting matters, governance updates, operating results and legal developments tied to corporate finance disputes.
Vystar (OTCQB: VYST) announced a planned tax-free spin-off of its RXAIR air purification business into a new publicly traded company, with Vystar shareholders to receive a pro rata dividend and Vystar retaining 9.99% ownership.
The plan includes a targeted completion by end of October 2026, a controlling partner to acquire at least 51%, and approximately $10 million of RXAIR tax loss carryforwards.
Vystar (OTCQB: VYST) and Capital Realm launched R3alm.com on April 21, 2026, and announced a proposed strategic transaction where Vystar would acquire a 50% interest in R3alm, Inc.
The platform targets tokenization, AI-driven compliance, private markets and a proposed R3EQ equity token, citing third-party estimates that the tokenized asset market could reach $2–$5 trillion by 2030.
Vystar (OTCQB: VYST) entered a binding letter of intent to acquire a 50% interest in R3alm, a compliance-focused AI and Web3 financial ecosystem. Consideration includes approximately 8,500 shares of Vystar Series B preferred stock and an R3EQ token allocation.
R3alm comprises 22 planned modules spanning tokenized assets, governance, trading, treasury, identity, analytics and an AI financial intelligence layer. Closing is anticipated in less than 60 days, subject to definitive agreements, due diligence and board approvals. Management cites a market opportunity of $2–5 trillion near term, up to $10 trillion longer term.
Vystar (OTCQB: VYST) launches a 14-day free memorabilia sweepstakes beginning February 18, 2026, driven by a social media push on X to promote the GoPaid collectibles ecosystem and tokenization initiatives.
Daily prizes ($25–$250 ARV) awarded Monday–Friday; winners contacted via X @JRC_Stocks. Vystar announced a partnership with GoPaid and Capital R3alm to pursue tokenized collectibles, a R3alm marketplace targeted for Q2 2026, and an oracle network for valuations and provenance.
Vystar (OTCQB: VYST) acquired 100% of Fluid Energy Conversion (FEC) assets, including the patented Hughes Reactor, and says a water filtration enhancement device is in final prototype testing to improve dialysis efficiency. Vystar expects FEC tech to reduce RxAir purifier size and cost, boost pathogen kill rates, and enable eco-friendly product initiatives across water, metering, and medical uses.
The company cites an estimated 1.7 billion gallons saved for one dialysis company and anticipates completing final testing in the current quarter.
Vystar (OTCQB: VYST) submitted a binding Letter of Intent dated Dec 4, 2025 to acquire a minority equity stake in GoPaid.com LLC and a percentage of GoPaid’s proprietary cryptocurrency or the lesser of a $10 million valuation.
The initial purchase price is 1,000 shares of Series C preferred common stock, with options to acquire up to an additional 10% equity and 3% cryptocurrency/b over two years, exercisable semi-annually. Target closing is on or before . Vystar committed to help raise $250,000 and to partner with Capital R3alm to launch R3alm Oracle and a Q2 2026 white-label R3alm Collectibles marketplace.
Vystar (OTCQB: VYST) announced a court victory dated Dec. 22, 2025 after four years of litigation against EMA Financial that resulted in dismissal of EMA’s suit seeking damages “in excess of $4,226,187.”
The U.S. Court of Appeals for the Second Circuit denied EMA’s appeal and the court awarded Vystar $497,439.58 in legal fees and costs. Vystar thanked its litigation and corporate counsel and named outside accountants who supported the case.
Vystar (OTCQB: VYST) announced that Internet and Incubator Stock Review initiated coverage on October 24, 2025, citing Vystar’s portfolio of four start-ups and development support for management, structuring and marketing.
Highlights include Vytex latex alternatives for medical and consumer uses, FDA-cleared RxAir 400 air purifier covering up to 800 sq ft, energy technologies at FEC, and a planned GoPaid.com tokenization portal with a full launch expected in Q4 2025 and a BETA imminent. The research firm emphasized tokenization’s potential to expand access to the collectibles and fine art market.
Vystar (OTCQB: VYST) announced on October 17, 2025 that the Vytex® Cloud Bed-in-a-Box collection is available for sale exclusively at www.vytex.com.
The line features 100% natural deproteinized Vytex latex in three support levels (firm, plush, super plush), six sizes, a 9-inch thickness, a quilted organic cotton over Joma wool cover, a free topper, and optional pillows and toppers. Product claims include 99.8% protein removal, a 90% stronger bond for durability, full biodegradability, and an expected useful life of 20+ years. Bed-in-a-Box industry sales are noted at nearly 35% of mattress sales.
Vystar Corporation (OTCQB: VYST) announced the relaunch of its Vytex® Cloud Bed-in-a-Box mattress collection, targeting the rapidly growing $30 billion mattress industry. The product line features 100% natural latex mattresses available in three support levels and six sizes, with bed-in-a-box sales now representing nearly 30% of all mattress sales.
The 9-inch thick mattresses will be available from October 1st, 2025, featuring a quilted organic cotton over Joma™ wool cover. Key product features include 20+ years of durability, natural antimicrobial properties, and Vystar's multi-patented deproteinization technology that removes 99.8% of allergy-causing proteins. The company offers a 100-day free trial and a 10-year warranty against manufacturing defects.